The Ordinary Multi-Peptide + HA Serum: the serum behind the eight-week claim

The US product page identifies Multi-Peptide + HA Serum and describes its format as water-based. Its key-ingredient list includes sodium hyaluronate and several named peptides. The same page points readers toward Multi-Peptide + Copper Peptides 1% Serum as a different product. Similar names do not make those two ingredient records interchangeable. The Ordinary HA serum record.

This review therefore follows the HA preparation’s own claims and evidence. It does not borrow a copper amount or a result from the neighboring serum. The broader product comparison is a place to navigate distinct reviews, with each preparation retaining its own identity.

The current page names five peptide technologies, including Matrixyl 3000, SYN-AKE and ARGIRELOX. It combines these with amino acids and hyaluronic acid complexes in its description. The technology count describes the manufacturer’s formulation story; it does not tell us that five separate trials tested the finished serum. Current technology description.

The information returned includes a key-ingredient list, rather than a complete ordered declaration for this review. That limits how precisely the whole formula can be described. Concentrations and a particular purchased package are not verified here. The Naturium review offers another separately sourced product discussion, without implying the formulas are equivalent.

The product FAQ reports an independent efficacy study involving 30 individuals over eight weeks. It associates that summary with crow’s-feet appearance, smoothness and texture, elasticity and firmness. This is a manufacturer account of testing, not an independently obtained full report. The term independent belongs to the company’s description of the study. The Ordinary testing FAQ.

The summary does not provide enough detail to reconstruct how each endpoint was measured, what comparison was used or which participant characteristics mattered. Those missing details affect interpretation. An eight-week statement can identify the scope of a reported test without supplying an expected degree of change for every person who buys the serum.

The manufacturer’s peptide guide describes the original Multi-Peptide + HA Serum as using four peptide technologies. The current product page describes five. Both records concern the named HA serum, but their wording should not be silently harmonized into a single count. The Ordinary peptide guide and current product description.

That difference alone does not prove a reformulation or date one. It does show why a technology description needs a specific product version when linked to testing. A useful question would ask which formulation was used in the 30-person study and how it corresponds to the currently supplied ingredient declaration.

The AAD discusses peptides among options considered for the appearance of slack skin and wrinkles during menopause. This is relevant background for understanding why a peptide serum might appear in a facial-care discussion. It is not a test of this serum, its named complexes or its manufacturer’s reported eight-week results. AAD menopause skin guidance.

The product record remains the source for the serum-specific claims. General professional guidance should not be presented as an endorsement of the 30-person test. The hydration and firmness guide provides further reading on distinguishing the appearance associated with moisture from other claimed changes.

The reviewed US product page displayed $19.90 alongside a reduced amount of $17.91. It did not identify the selected size for that displayed offer in the product information available here. Those amounts therefore should not be attached to an assumed bottle quantity or used to calculate a verified price per unit. The Ordinary US listing.

The distinction is practical: a promotional price and a complete size-price pairing are different pieces of information. No purchase or stock check was performed. The Olay serum review is another individual review to explore, while this serum’s size-specific commercial question remains unresolved.

A fuller account would connect the tested preparation to the current ingredient declaration and explain each result’s method and comparison. The manufacturer’s guide also acknowledges that results vary with the product, use and individual concern. That qualification is important when reading a compact testing headline as though it were a personal forecast. The Ordinary guide and study summary.

The serum can be discussed for its named ingredients and advertised appearance goals without giving it an estrogen-treatment role. For interpreting visible changes more carefully, the photo-evidence guide is useful further reading. It does not turn a photograph into the missing trial report.